The oral absorption of ordinary bismuth compounds is too inconstant and too slight for reliable antisyphilitic action. Several special compounds have been introduced with claims that they have produced clinical and serologic benefit in syphilis. We have tried two of these, but found them clinically inactive and the excretion produced insignificant. Recently Hanzlik and his associates1 introduced a new type of compound, sobisminol (sodium bismuthate soluble), and reported it to be effective for oral as well as intramuscular administration and to produce a urinary excretion equal to that of the ordinary compounds for intramuscular injection. As we have developed a somewhat standardized technic for comparing the excretion produced by the various bismuth compounds, it appeared interesting to see how the excretion produced by this new compound, especially when administered orally, compared with that of the other compounds of which we have records and to attempt to attempt to correlate
SOLLMANN T, COLE H, HENDERSON K, et al. CLINICAL EXCRETION OF BISMUTHV. EXCRETION OF SOBISMINOL AND OF SOME OTHER BISMUTH PREPARATIONS FOR ORAL ADMINISTRATION. Arch Derm Syphilol. 1938;37(6):993–1002. doi:10.1001/archderm.1938.01480120059010
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: